Full 2015 Annual Report (1.6 MB)
2015 Annual Report Selected Highlights
NIH Opens Hospital to Outside Scientists, Tackles Disease on Many Fronts
Starting in 2014, academic and industry scientists were able to conduct medical research at the Clinical Center. This opportunity involves three year, renewable awards of up to $500,000 per year and access to the research hospital's extraordinary facilities and staff. The National Institutes of Health (NIH) regularly provides funding for scientists outside of its organization, called extramural researchers, and government scientists who work for NIH directly, called intramural researchers. With this new program, outside scientists will now be able to test promising laboratory discoveries using emerging technologies and tools. Researchers will also be able to collaborate on clinical protocols, often for extraordinarily rare diseases, in partnership with NIH investigators to help advance disease diagnosis, treatment and prevention.
The awards will support projects focusing on a variety of diseases and health conditions that affect children and adults in the United States and worldwide. (See text below for more details.)
"We are very excited about opening the doors of the Clinical Center to our extramural colleagues who will bring additional cutting-edge research projects and new partnerships that will enrich ongoing efforts translating scientific discovery into tomorrow's cures at the Clinical Center and in partnering institutions around the country," said Dr. John I. Gallin, director of the NIH Clinical Center.
The Clinical Center is hosting new collaboration projects with outside researchers, including:
A clinical trial for a new drug treatment for Niemann Pick C, a rare, fatal disease caused by the loss of the ability to break down cholesterol and other fats. Sponsored by Washington University.
A clinical trial of a new drug treatment to prevent relapse in a form of childhood leukemia. Sponsored by the Children's Research Institute.
A clinical trial to understand the genetic makeup of certain types of prostate cancer, to gain insights that could yield new information for prevention and treatment efforts. Sponsored by the University of Michigan.
Development of a new catheter that can be threaded into the heart to relay high-quality images needed for making surgical and treatment decisions. Sponsored by the Georgia Institute of Technology.
A long-term, follow-up study of patients treated for Cryptococcus gattii, an airborne fungus that can cause severe, sometimes fatal, respiratory infections. Sponsored by John's Hopkins University.
A clinical trial of a new vaccine to prevent malaria. Sponsored by Sanaria, Inc.
A clinical study of Moebius Syndrome, a birth defect that limits the ability to make facial expressions like smiles or frowns and can create difficulty in swallowing, blinking or breathing. Sponsored by the Icahn School of Medicine at Mount Sinai.
A clinical study to evaluate if a chemotherapy treatment regimen used to treat cancer is also effective in treating the human immunodeficiency virus (HIV). Sponsored by City of Hope and the Beckman Research Institute.
A clinical study of a medication to treat the immune disorder common variable immune deficiency (CVID) enteropathy. Sponsored by Oregon State University.
A long-term study of patients with a genetic mutation of the STAT1 protein that regulates cell growth and development. Sponsored by Rockefeller University.
NOTE: PDF documents require the free Adobe Reader.
This page last updated on 07/27/2017